111 Inc. (YI) - חוב להון עצמי

111, Inc. (YI) is expanding digital pharmaceutical distribution while facing a geopolitical rift between the US and China, as well as the threat of delisting. Operations are complicated by minimal profitability and government price controls. This chart of the total debt-to-equity metric reflects a level of 0.00. Meanwhile, the business relies on a robust B2B infrastructure that leverages network effects and software to increase customer switching costs.

Logistics optimization and the digitalization of document workflows at 111, Inc. (YI) require capital expenditures that can be funded through either retained earnings or debt. By analyzing the company's financial leverage history, an investor evaluates the total liabilities-to-equity ratio, which determines the business's dependence on external borrowing and the risks of balance sheet overload amid fluctuating interest rates.